Summary

Growth Hormone Deficiency Market Research Report Forecast to 2027

Market Overview
The Growth Hormone Deficiency Market is anticipated to register a healthy CAGR of 4.19% during the review period.
The growth hormone deficiency market is encountering critical growth driven by headways in analysis, expanding mindfulness, and extending treatment choices. Developing acknowledgment of the effect of growth hormone deficiency on wellbeing, combined with progressing research and improvement endeavors, positions this market for proceeded with extension soon.
The growth of the Growth Hormone Deficiency Market is supposed to be driven by the rising number of people experiencing growth hormone deficiency (GHD), rising mindfulness in regard to the adequacy of GH alongside clinical preliminaries zeroed in on the security and viability of GHD, and the changing way of life alongside the developing predominance of hereditary problems.
As per the distributed article in NCBI in Walk 2017, the assessed commonness of GHD is roughly 2-3 out of 10,000 populaces. GHD is brought about by primary pituitary sickness or cranial illumination and happens with regards to extra elements of hypopituitarism. Pituitary adenomas are reported to cause grown-up beginning GHD followed by craniopharyngiomas, which represents roughly 57% of cases. What's more, adolescence beginning growth hormone deficiency (CO-GHD) is one of the perplexing endocrine circumstances that might have an effect over the course of life, beginning in youth, and going on till adulthood. Most of the CO-GH is reported to be intrinsic. The fundamental co-morbidities and side effects of GHD in grown-ups and kids are heftiness, diabetes mellitus, hypertension, cerebrovascular illnesses, cardiovascular sicknesses, and liver sicknesses. This rising bleakness of GH sickness in the two kids and grown-ups is supposed to drive the growth of the growth hormone deficiency market.
Market Segmentation
Norditropin, Genotropin, Humatrope, Saizen, Omnitrope, and more brands are included in the Growth Hormone Deficiency Market segmentation based on brand.
The market is divided into categories according to the application: prader-willi syndrome, turner syndrome, adult growth hormone deficit, small for gestational age, idiopathic short stature, and others.
The subcutaneous, intramuscular, and intravenous routes of delivery are used to segment the growth hormone deficiency market. Clinics, e-commerce websites, hospital pharmacies, and retail pharmacies make up the market's distribution channels.
Regional Insights
The Americas growth hormone deficiency market represented the biggest market share in 2022. Key elements ascribed to its huge offer incorporate created medical services framework, expanding mechanical headway, and the presence of many market players in the region.
Europe growth hormone deficiency market represented the second-biggest market share because of developing predominance of GHD people, and the rising attention to treatment.
The Asia-Pacific growth hormone deficiency market is supposed to be the quickest developing from 2023 to 2027 because of developing progression in treatment, expanding assets in research exercises, and rising pervasiveness of GHD.
Major Players
Key Companies in the Growth Hormone Deficiency market includes Novo Nordisk A/S (Denmark), Pfizer, Inc. (US), Merck KGaA (Germany), Eli Lily and Company (Netherlands), Novartis AG (Switzerland), Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Ispen Pharma (Switzerland), Ferring Pharmaceuticals (Switzerland), AnkeBio Co., Ltd (China), and Zhongshan Sinobioway Hygene Biomedicine Co., Ltd (China).

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION

2.2 SCOPE OF THE STUDY

2.3 RESEARCH OBJECTIVE

2.4 MARKET STRUCTURE

2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

3.1 DATA MINING

3.2 SECONDARY RESEARCH

3.3 PRIMARY RESEARCH

3.4 BREAKDOWN OF PRIMARY RESPONDENTS

3.5 FORECASTING TECHNIQUES

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION

3.6.1 BOTTOM-UP APPROACH

3.6.2 TOP-DOWN APPROACH

3.7 DATA TRIANGULATION

3.8 VALIDATION

4 MARKET DYNAMICS

4.1 OVERVIEW

4.2 DRIVERS

4.2.1 INCREASING INCIDENCE OF GROWTH HORMONE DEFICIENCY

4.2.2 RISING NUMBER OF CLINICAL TRIAL FOR GH DEFICIENCY

4.2.3 GOVERNMENT INITIATIVES FOR GHD

4.2.4 INCREASING NUMBER OF PRODUCT LAUNCH AND STRATEGIC COLLABORATIONS AMONG MARKET PLAYERS

4.3 RESTRAINTS

4.3.1 HIGH COST OF GHD TREATMENT

4.3.2 INCREASING COUNTERFEIT PRODUCTS FOR GHD TREATMENT

4.4 OPPORTUNITIES

4.4.1 STRONG PIPELINE OF HORMONAL DRUGS AND EASY AVAILABILITY OF PHARMA DRUGS ON E-COMMERCE PLATFORMS

4.5 CLINICAL TRIALS ANALYSIS

4.6 MEGATRENDS

4.6.1 ADVENT OF LONG-ACTING RECOMBINANT HUMAN GROWTH HORMONE (RHGH)

4.6.2 USE OF HGH AS PERFORMANCE ENHANCERS AND ANTI-AGING AGENTS

4.6.3 PRODUCTS UNDER DEVELOPMENT

4.7 MACROECONOMIC INDICATORS

4.8 GOVERNMENT REGULATIONS AND NEW TREATMENT SCHEMES

4.9 LONG ACTING GROWTH HORMONES (LAGH)

4.9.1 OVERVIEW

4.9.2 DEVELOPMENT

4.9.3 UPCOMING PRODUCTS

4.9.4 TRENDS

5 MARKET FACTOR ANALYSIS

5.1 SUPPLY CHAIN ANALYSIS

5.1.1 RESEARCH AND DEVELOPMENT

5.1.2 MANUFACTURING

5.1.3 DISTRIBUTION

5.1.4 MARKETING AND SALES

5.1.5 POST-SALES MONITORING

5.2 PORTER’S FIVE FORCES MODEL

5.2.1 THREAT OF NEW ENTRANTS

5.2.2 BARGAINING POWER OF SUPPLIERS

5.2.3 THREAT OF SUBSTITUTES

5.2.4 BARGAINING POWER OF BUYERS

5.2.5 RIVALRY

5.3 IMPACT OF COVID-19

5.3.1 OVERVIEW

5.3.2 IMPACT ON SUPPLY CHAIN

5.3.3 IMPACT ON PRODUCTION

5.4 EPIDEMIOLOGY DATA ON TYPE OF GROWTH HORMONE DEFICIENCY DISEASES (2022)

6 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY BRAND

6.1 OVERVIEW

6.2 NORDITROPIN

6.3 GENOTROPIN

6.4 HUMATROPE

6.5 SAIZEN

6.6 OMNITROPE

7 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION

7.1 OVERVIEW

7.2 PAEDIATRIC GROWTH HORMONE DEFICIENCY

7.3 IDIOPATHIC SHORT STATURE

7.4 SMALL FOR GESTATIONAL AGE

7.5 TURNER SYNDROME

7.6 ADULT GROWTH HORMONE DEFICIENCY

7.7 PRADER-WILLI SYNDROME

8 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION

8.1 OVERVIEW

8.2 SUBCUTANEOUS

8.3 INTRAMUSCULAR

8.4 INTRAVENOUS

9 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL

9.1 OVERVIEW

9.2 HOSPITAL PHARMACIES

9.3 RETAIL PHARMACIES

9.4 CLINICS

9.5 E-COMMERCE WEBSITES

10 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY REGION

10.1 OVERVIEW

10.2 AMERICAS

10.2.1 NORTH AMERICA

10.2.1.1 US

10.2.1.2 CANADA

10.2.2 LATIN AMERICA

10.3 EUROPE

10.3.1 WESTERN EUROPE

10.3.1.1 GERMANY

10.3.1.2 FRANCE

10.3.1.3 UK

10.3.1.4 ITALY

10.3.1.5 SPAIN

10.3.1.6 REST OF WESTERN EUROPE

10.3.2 EASTERN EUROPE

10.4 ASIA-PACIFIC

10.4.1 JAPAN

10.4.2 CHINA

10.4.3 INDIA

10.4.4 AUSTRALIA

10.4.5 SOUTH KOREA

10.4.6 REST OF ASIA-PACIFIC

10.5 MIDDLE EAST AND AFRICA

10.5.1 MIDDLE EAST

10.5.2 AFRICA

11 COMPETITIVE LANDSCAPE

11.1 OVERVIEW

11.2 GLOBAL GROWTH HORMONE DEFICIENCY MARKET SHARE ANALYSIS (2019)

11.3 COMPETITIVE BENCHMARKING

11.4 MAJOR GROWTH STRATEGIES IN THE GLOBAL GROWTH HORMONE DEFICIENCY MARKET

11.5 THE LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL GROWTH HORMONE DEFICIENCY MARKET

11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES

11.6.1 EXPANSION

11.6.2 PRODUCT APPROVAL/FDA APPROVAL

12 COMPANY PROFILES

12.1 MERCK KGAA

12.1.1 COMPANY OVERVIEW

12.1.2 FINANCIAL OVERVIEW

12.1.3 PRODUCTS/SERVICES OFFERED

12.1.4 KEY DEVELOPMENTS

12.1.5 SWOT ANALYSIS

12.1.6 KEY STRATEGIES

12.2 NOVO NORDISK A/S

12.2.1 COMPANY OVERVIEW

12.2.2 FINANCIAL OVERVIEW

12.2.3 PRODUCTS/SERVICES OFFERED

12.2.4 KEY DEVELOPMENTS

12.2.5 SWOT ANALYSIS

12.2.6 KEY STRATEGIES

12.3 ELI LILY AND COMPANY

12.3.1 COMPANY OVERVIEW

12.3.2 FINANCIAL OVERVIEW

12.3.3 PRODUCTS/SERVICES OFFERED

12.3.4 KEY DEVELOPMENTS

12.3.5 SWOT ANALYSIS

12.3.6 KEY STRATEGIES

12.4 F. HOFFMAN LA ROCHE LTD

12.4.1 COMPANY OVERVIEW

12.4.2 FINANCIAL OVERVIEW

12.4.3 PRODUCTS/SERVICES OFFERED

12.4.4 KEY DEVELOPMENTS

12.4.5 SWOT ANALYSIS

12.4.6 KEY STRATEGIES

12.5 PFIZER, INC.

12.5.1 COMPANY OVERVIEW

12.5.2 FINANCIAL OVERVIEW

12.5.3 PRODUCTS/SERVICES OFFERED

12.5.4 KEY DEVELOPMENTS

12.5.5 SWOT ANALYSIS

12.5.6 KEY STRATEGIES

12.6 NOVARTIS AG

12.6.1 COMPANY OVERVIEW

12.6.2 FINANCIAL OVERVIEW

12.6.3 PRODUCTS/SERVICES OFFERED

12.6.4 KEY DEVELOPMENTS

12.6.5 SWOT ANALYSIS

12.6.6 KEY STRATEGIES

12.7 IPSEN PHARMA

12.7.1 COMPANY OVERVIEW

12.7.2 FINANCIAL OVERVIEW

12.7.3 PRODUCTS/SERVICES OFFERED

12.7.4 KEY DEVELOPMENTS

12.7.5 SWOT ANALYSIS

12.7.6 KEY STRATEGIES

12.8 FERRING PHARMACEUTICALS

12.8.1 COMPANY OVERVIEW

12.8.2 FINANCIAL OVERVIEW

12.8.3 PRODUCTS/SERVICES OFFERED

12.8.4 KEY DEVELOPMENTS

12.8.5 SWOT ANALYSIS

12.8.6 KEY STRATEGIES

12.9 ANKEBIO CO., LTD

12.9.1 COMPANY OVERVIEW

12.9.2 FINANCIAL OVERVIEW

12.9.3 PRODUCTS/SERVICES OFFERED

12.9.4 KEY DEVELOPMENTS

12.9.5 SWOT ANALYSIS

12.9.6 KEY STRATEGIES

12.10 ZHONGSHAN SINOBIOWAY HYGENE BIOMEDICINE CO., LTD

12.10.1 COMPANY OVERVIEW

12.10.2 FINANCIAL OVERVIEW

12.10.3 PRODUCTS/SERVICES OFFERED

12.10.4 KEY DEVELOPMENTS

12.10.5 SWOT ANALYSIS

12.10.6 KEY STRATEGIES

13 APPENDIX

13.1 REFERENCES

13.2 RELATED REPORTS

ページTOPに戻る

List of Tables/Graphs

LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS

TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS

TABLE 3 CLINICAL TRIALS OVERVIEW

TABLE 4 TREATMENT WITH GROWTH HORMONE AND TERMS OF REIMBURSEMENT IN EUROPEAN COUNTRIES

TABLE 5 COUNTRIES OVERVIEW

TABLE 6 SUMMARY OF LAGH PREPARATION BASED ON CLASS

TABLE 7 WORLDWIDE EPIDEMIOLOGY DATA

TABLE 8 US: EPIDEMIOLOGY DATA

TABLE 9 UK: EPIDEMIOLOGY DATA

TABLE 10 ITALY: EPIDEMIOLOGY DATA

TABLE 11 GERMANY: EPIDEMIOLOGY DATA

TABLE 12 SPAIN: EPIDEMIOLOGY DATA

TABLE 13 FRANCE: EPIDEMIOLOGY DATA

TABLE 14 JAPAN: EPIDEMIOLOGY DATA

TABLE 15 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2027 (USD MILLION)

TABLE 16 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR NORDITROPIN, BY REGION, 2022-2027 (USD MILLION)

TABLE 17 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR GENOTROPIN, BY REGION, 2019-2027 (USD MILLION)

TABLE 18 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR HUMATROPE, BY REGION, 2019-2027 (USD MILLION)

TABLE 19 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR SAIZEN, BY REGION, 2019-2027 (USD MILLION)

TABLE 20 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR OMNITROPE, BY REGION, 2019-2027 (USD MILLION)

TABLE 21 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2019-2027 (USD MILLION)

TABLE 22 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR PAEDIATRIC GROWTH HORMONE DEFICIENCY, BY REGION, 2019-2027 (USD MILLION)

TABLE 23 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR IDIOPATHIC SHORT STATURE, BY REGION, 2019-2027 (USD MILLION)

TABLE 24 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR SMALL FOR GESTATIONAL AGE, BY REGION, 2019-2027 (USD MILLION)

TABLE 25 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR TURNER SYNDROME, BY REGION, 2019-2027 (USD MILLION)

TABLE 26 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR ADULT GROWTH HORMONE DEFICIENCY, BY REGION, 2019-2027 (USD MILLION)

TABLE 27 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR PRADER-WILLI SYNDROME, BY REGION, 2019-2027 (USD MILLION)

TABLE 28 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)

TABLE 29 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR SUBCUTANEOUS, BY REGION, 2022-2027 (USD MILLION)

TABLE 30 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR INTRAMUSCULAR, BY REGION, 2019-2027 (USD MILLION)

TABLE 31 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR INTRAVENOUS, BY REGION, 2019-2027 (USD MILLION)

TABLE 32 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)

TABLE 33 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2019-2027 (USD MILLION)

TABLE 34 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR RETAIL PHARMACIES, BY REGION, 2019-2027 (USD MILLION)

TABLE 35 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR CLINICS, BY REGION, 2019-2027 (USD MILLION)

TABLE 36 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR E-COMMERCE WEBSITES, BY REGION, 2019-2027 (USD MILLION)

TABLE 37 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY REGION, 2019-2027 (USD MILLION)

TABLE 38 AMERICAS: GROWTH HORMONE DEFICIENCY MARKET, BY REGION, 2019-2027 (USD MILLION)

TABLE 39 AMERICAS: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2027 (USD MILLION)

TABLE 40 AMERICAS: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2019-2027 (USD MILLION)

TABLE 41 AMERICAS: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)

TABLE 42 AMERICAS: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)

TABLE 43 NORTH AMERICA: GROWTH HORMONE DEFICIENCY MARKET, BY COUNTRY, 2019-2027 (USD MILLION)

TABLE 44 NORTH AMERICA: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2027 (USD MILLION)

TABLE 45 NORTH AMERICA: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2019-2027 (USD MILLION)

TABLE 46 NORTH AMERICA: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)

TABLE 47 NORTH AMERICA: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)

TABLE 48 US: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2027 (USD MILLION)

TABLE 49 US: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2019-2027 (USD MILLION)

TABLE 50 US: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)

TABLE 51 US: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)

TABLE 52 CANADA: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2027 (USD MILLION)

TABLE 53 CANADA: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2019-2027 (USD MILLION)

TABLE 54 CANADA: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2027 (USD MILLION)

TABLE 55 CANADA: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2017-2027 (USD MILLION)

TABLE 56 LATIN AMERICA: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2027 (USD MILLION)

TABLE 57 LATIN AMERICA: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2019-2027 (USD MILLION)

TABLE 58 LATIN AMERICA: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)

TABLE 59 LATIN AMERICA: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)

TABLE 60 EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY REGION, 2019-2027 (USD MILLION)

TABLE 61 EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2027 (USD MILLION)

TABLE 62 EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2019-2027 (USD MILLION)

TABLE 63 EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2027 (USD MILLION)

TABLE 64 EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)

TABLE 65 WESTERN EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY COUNTRY, 2019-2027 (USD MILLION)

TABLE 66 WESTERN EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2027 (USD MILLION)

TABLE 67 WESTERN EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2022-2027 (USD MILLION)

TABLE 68 WESTERN EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)

TABLE 69 WESTERN EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)

TABLE 70 GERMANY: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2027 (USD MILLION)

TABLE 71 GERMANY: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2019-2027 (USD MILLION)

TABLE 72 GERMANY: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)

TABLE 73 GERMANY: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)

TABLE 74 FRANCE: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2027 (USD MILLION)

TABLE 75 FRANCE: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2019-2027 (USD MILLION)

TABLE 76 FRANCE: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2027 (USD MILLION)

TABLE 77 FRANCE: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)

TABLE 78 UK: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2027 (USD MILLION)

TABLE 79 UK: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2019-2027 (USD MILLION)

TABLE 80 UK: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2027 (USD MILLION)

TABLE 81 UK: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)

TABLE 82 ITALY: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2027 (USD MILLION)

TABLE 83 ITALY: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2019-2027 (USD MILLION)

TABLE 84 ITALY: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)

TABLE 85 ITALY: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)

TABLE 86 SPAIN: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2027 (USD MILLION)

TABLE 87 SPAIN: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2019-2027 (USD MILLION)

TABLE 88 SPAIN: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)

TABLE 89 SPAIN: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)

TABLE 90 REST OF WESTERN EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2027 (USD MILLION)

TABLE 91 REST OF WESTERN EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2019-2027 (USD MILLION)

TABLE 92 REST OF WESTERN EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)

TABLE 93 REST OF WESTERN EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)

TABLE 94 EASTERN EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2027 (USD MILLION)

TABLE 95 EASTERN EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2019-2027 (USD MILLION)

TABLE 96 EASTERN EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)

TABLE 97 EASTERN EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)

TABLE 98 ASIA-PACIFIC: GROWTH HORMONE DEFICIENCY MARKET, BY COUNTRY, 2019-2027 (USD MILLION)

TABLE 99 ASIA-PACIFIC: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2027 (USD MILLION)

TABLE 100 ASIA-PACIFIC: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2019-2027 (USD MILLION)

TABLE 101 ASIA-PACIFIC: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)

TABLE 102 ASIA-PACIFIC: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)

TABLE 103 JAPAN: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2027 (USD MILLION)

TABLE 104 JAPAN: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2019-2027 (USD MILLION)

TABLE 105 JAPAN: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)

TABLE 106 JAPAN: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)

TABLE 107 CHINA: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2027 (USD MILLION)

TABLE 108 CHINA: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2019-2027 (USD MILLION)

TABLE 109 CHINA: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)

TABLE 110 CHINA: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)

TABLE 111 INDIA: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2027 (USD MILLION)

TABLE 112 INDIA: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2019-2027 (USD MILLION)

TABLE 113 INDIA: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)

TABLE 114 INDIA: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)

TABLE 115 AUSTRALIA: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2027 (USD MILLION)

TABLE 116 AUSTRALIA: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2019-2027 (USD MILLION)

TABLE 117 AUSTRALIA: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)

TABLE 118 AUSTRALIA: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)

TABLE 119 SOUTH KOREA: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2027 (USD MILLION)

TABLE 120 SOUTH KOREA: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2019-2027 (USD MILLION)

TABLE 121 SOUTH KOREA: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)

TABLE 122 SOUTH KOREA: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)

TABLE 123 REST OF ASIA-PACIFIC: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2027 (USD MILLION)

TABLE 124 REST OF ASIA-PACIFIC: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2019-2027 (USD MILLION)

TABLE 125 REST OF ASIA-PACIFIC: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)

TABLE 126 REST OF ASIA-PACIFIC: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)

TABLE 127 MIDDLE EAST & AFRICA: GROWTH HORMONE DEFICIENCY MARKET, BY REGION, 2019-2027 (USD MILLION)

TABLE 128 MIDDLE EAST & AFRICA: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2027 (USD MILLION)

TABLE 129 MIDDLE EAST & AFRICA: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2019-2027 (USD MILLION)

TABLE 130 MIDDLE EAST & AFRICA: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)

TABLE 131 MIDDLE EAST & AFRICA: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)

TABLE 132 MIDDLE EAST: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2027 (USD MILLION)

TABLE 133 MIDDLE EAST: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2019-2027 (USD MILLION)

TABLE 134 MIDDLE EAST: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)

TABLE 135 MIDDLE EAST: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)

TABLE 136 AFRICA: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2027 (USD MILLION)

TABLE 137 AFRICA: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2019-2027 (USD MILLION)

TABLE 138 AFRICA: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)

TABLE 139 AFRICA: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)

TABLE 140 THE MOST ACTIVE PLAYER IN THE GLOBAL GROWTH HORMONE DEFICIENCY MARKET

TABLE 141 EXPANSION

TABLE 142 PRODUCT APPROVAL/FDA APPROVAL

TABLE 143 MERCK KGAA: PRODUCTS/SERVICES OFFERED

TABLE 144 MERCK KGAA: KEY DEVELOPMENTS

TABLE 145 NOVO NORDISK A/S: PRODUCTS/SERVICES OFFERED

TABLE 146 NOVO NORDISK A/S: KEY DEVELOPMENT

TABLE 147 ELI LILY AND COMPANY: PRODUCTS/SERVICES OFFERED

TABLE 148 F. HOFFMAN LA ROCHE LTD: PRODUCTS/SERVICES OFFERED

TABLE 149 PFIZER INC.: PRODUCTS/SERVICES OFFERED

TABLE 150 NOVARTIS AG: PRODUCTS/SERVICES OFFERED

TABLE 151 IPSEN PHARMA: PRODUCTS/SERVICES OFFERED

TABLE 152 FERRING PHARMACEUTICALS: PRODUCTS/SERVICES OFFERED

TABLE 153 FERRING PHARMACEUTICALS: KEY DEVELOPMENT

TABLE 154 ANKEBIO CO., LTD: PRODUCTS/SERVICES OFFERED

TABLE 155 ZHONGSHAN SINOBIOWAY HYGENE BIOMEDICINE CO., LTD: PRODUCTS/SERVICES OFFERED